Abstract: The invention relates to a dimeric complex of a selectively deglycosylated vitamin D-binding protein (GcMAF) and cholecalciferol (calciol). The invention further relates to a method for producing such a complex, wherein a vitamin D-binding protein is reacted with calciol and is selectively deglycosylated before or after being reacted. The resulting product is finally separated from impurities with a larger molecular weight, in particular enzymes of the selective deglycosylation process, using a molecular sieve with a cutoff value of more than 60 kDa.

Abstract: The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with colorectal cancer compared to subjects without colorectal cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease progression or regression in a patient and the efficacy of therapeutic regimens.

Abstract: The present invention relates to a computer-implemented method of producing a kinetic model of a biological network. An example method can comprise choosing a network topology. The nodes of said topology represent biological entities and the edges of said topology represent interactions between said entities. An example method can comprise assigning kinetic laws and kinetic constants to said interactions and assigning starting concentrations to said biological entities. One part of said kinetic constants and independently one part of said starting concentrations are experimental data. The remaining part of said kinetic constants and independently the remaining part of said starting concentrations are chosen randomly.

Abstract: The present invention relates to a computer-implemented method of producing a kinetic model of a biological network, the method comprising (a) choosing a network topology, wherein the nodes of said topology represent biological entities and the edges of said topology represent interactions between said entities; (b) assigning kinetic laws and kinetic constants to said interactions; and (c) assigning starting concentrations to said biological entities, wherein (i) one part of said kinetic constants and independently one part of said starting concentrations are experimental data; and (ii) the remaining part of said kinetic constants and independently the remaining part of said starting concentrations are chosen randomly.

Abstract: Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can be used in the form of an infusion, in an oral or rectal form of administration, or as an irrigation in cancer therapy.

Abstract: Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can be used in the form of an infusion, in an oral or rectal form of administration, or as an irrigation in cancer therapy.

Abstract: The invention relates to a method and an analysis arrangement for the determination of characteristics and/or classification of circulating macrophages. A whole blood sample is subjected to a gradient centrifugation for isolating macrophages. The macrophage cells are then perforated and provided with an intracellular staining with at least one selected antibody. A flow cytometric analysis of the pre-treated cells enables a subsequent statistical evaluation of the cell contents. PSA, a cytokeratin and/or an epithelial membrane antigen are selected as antibodies.